Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: Strategic Focus on R&D Spending

Teva vs. Arrowhead: A Decade of R&D Investment

__timestampArrowhead Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014231380501488000000
Thursday, January 1, 2015574101471525000000
Friday, January 1, 2016414544522111000000
Sunday, January 1, 2017316902981848000000
Monday, January 1, 2018529685051213000000
Tuesday, January 1, 2019810486861010000000
Wednesday, January 1, 2020128874979997000000
Friday, January 1, 2021206342000967000000
Saturday, January 1, 2022297307000838000000
Sunday, January 1, 2023353188000953000000
Monday, January 1, 2024505870000998000000
Loading chart...

Unleashing the power of data

Strategic Focus on R&D: Teva vs. Arrowhead

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Teva Pharmaceutical Industries Limited and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.

A Decade of Investment

From 2014 to 2023, Teva's R&D expenses have shown a downward trend, decreasing by approximately 36% from their peak in 2016. This shift reflects Teva's strategic realignment amidst industry challenges. In contrast, Arrowhead has significantly ramped up its R&D spending, with a remarkable increase of over 2,000% during the same period, highlighting its aggressive pursuit of cutting-edge therapies.

The Road Ahead

As of 2023, Arrowhead's R&D expenditure reached its highest, while Teva's data for 2024 remains unavailable. This divergence underscores the dynamic nature of pharmaceutical innovation and the varied paths companies take to achieve growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025